Role of octreotide in small bowel bleeding

Table 2 Summary of the observational studies demonstrating the role of octreotide in left ventricular assist device-associated gastrointestinal bleeding

Ref.	Year	Patients’ number	Type of study	Treatment/prophylaxis	Route	Dose	Outcome
Hayes et al[92]	2010	5	Retrospective review	Octreotide treatment	Continuous infusion; subcutaneous injection; im injection	25 µg/min; 100 µg twice daily; 10 mg each month	GI bleeding was successfully treated in all cases
Aggarwal et al[93]	2012	101	Retrospective Univariate and multivariate regression analysis	Octreotide treatment	Continuous infusion or subcutaneous injection	N/A	No significant difference was noticed in the length of stay, units of packed red blood cells administered, re-bleeding episodes, or mortality
Dias et al[95]	2015	8	Retrospective review	Octreotide treatment	Subcutaneous injection or intravenous infusions	100 mcg TDS or BID	Cessation of bleeding in all cases
Smallfield et al[94]	2016	34	Retrospective cohort	Octreotide secondary prophylaxis	Subcutaneous & (LAR) depot injections	N/A	10 cases; re-bleed
Shah et al[96]	2017	51	Retrospective analysis	Octreotide secondary prophylaxis	38% LAR depot injection; 62% daily subcutaneous injection	N/A	73% ± 6% freedom from; re-bleeding for 6 mo; P = 0.7

N/A: Not applicable; IM: Intramuscular; GI: Gastrointestinal; RBCs: Red blood cells; TDS: Three times a day; BID: Two times a day.